



MULTIPLE MORBIDITIES


POINTS

<u>of VIEW</u>

AND THE GROWING RISE OF COMPLEX, COSTLY CARE

In the United States, the prevalence of multiple morbidities is increasing and expected to become further dire in the near future. Multiple morbidities are 2 or more medical or psychiatric chronic conditions that last for a year or more and which exist in the same patient. Such shift in the epidemiology of multiple morbidities stems from the rise in aging adults, increases in survivorship and life expectancy due to public health and medical interventions, and ongoing lifestyle risk factors that contribute to the diagnosis of chronic conditions. For pharmaceutical and biotechnology manufacturers, this urgent challenge presents a pivotal opportunity to address the care and cost complexities that emerge from patients who have multiple morbidities.

WHAT ARE THE KEY MULTIPLE MORBIDITY TRENDS IN THE UNITED STATES?







WHAT IS THE IMPACT OF MULTIPLE MORBIDITIES TO KEY HEALTH CARE STAKEHOLDERS?

IMPLICATIONS FOR PAYERS, **HEALTH SYSTEMS, AND PROVIDERS**

High cost care and wastage, especially if therapy management is not well-coordinated

POINTS

- Unestablished pathways to patient \$ identification and risk assessment
- Limited evidence base on treating patients Q with multiple morbidities
- Involved care coordination across multiple (**.**) therapeutic disciplines
 - Complex medication management and polypharmacy
 - Onerous access and reimbursement hurdles

IMPLICATIONS FOR PATIENTS

- Fluctuating day-to-day functioning and diminished quality of life
- Greater risk of treatment complications, ≫ adverse outcomes, hospitalizations, and death
- Conflicting, confusing, and complex care
 - communication from multiple providers
 - Increased burden of health care spend
 - Persistent need for caregiver and ancillary support

WHAT ROLE CAN MANUFACTURERS PLAY TO ADDRESS MULTIPLE MORBIDITIES?

\bigcirc

Design data-generating programs that evaluate the clinical and economic impact of multiple morbidities (eg, clinical trials, realworld evidence) and subsequently demonstrate how the brand can bring value



Invest in value-based initiatives for health system customers that support population health management and care coordination needs

1	7
(/)
~	

Partner with professional organizations to assess, enhance, or develop guidelines and standards of care that involve multiple morbidities

Demo n multipl
total co

nstrate value and outcomes from le morbidity management programs on st of care to health system and payer customers



Create patient solutions and services that expressly address the complexities of multiple morbidities (eg, adherence management, access support, caregiver resources)



Generate support resources for office staff on managing patients with multiple morbidities (eg, reimbursement tools, communication protocols, policy education)

MANUFACTURERS HAVE AN IMPORTANT AND TIMELY OPPORTUNITY TO DEMONSTRATE LEADERSHIP BY PROVIDING SOLUTIONS ACROSS THERAPEUTIC AREAS WITHIN THEIR PORTFOLIOS THAT ARE COMMONLY SUBJECT TO MULTIPLE MORBIDITIES.



Turn to McCann Health Managed Markets to help you with developing your strategy and solutions in addressing the care and cost complexities of multiple morbidities, so that ultimately patients can better navigate their health.

References: Agency for Healthcare Research and Quality; Buttroff C, Ruger T, Bauman M. Multiple chronic conditions in the United States; Centers for Disease Control and Prevention; Centers for Medicare & Medicaid Services; Whitson HE, Boyd CM. Managing multiple comorbidities; US Department of Health and Human Services

973.917.6500 | McCANNMANAGEDMARKETS.COM